Rinvoq

Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated.[8] It was approved for medical use in the United States and in the European Union in 2019,[8][9][5] and was developed by the biote... [wikipedia]